Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €61.97 EUR
Change Today +0.462 / 0.75%
Volume 237.1K
FRE On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Xetra
As of 4:53 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

fresenius se & co kgaa (FRE) Snapshot

Open
€61.95
Previous Close
€61.51
Day High
€62.84
Day Low
€61.75
52 Week High
08/18/15 - €66.56
52 Week Low
10/16/14 - €36.00
Market Cap
33.8B
Average Volume 10 Days
2.0M
EPS TTM
€2.16
Shares Outstanding
544.9M
EX-Date
05/21/15
P/E TM
28.7x
Dividend
€0.44
Dividend Yield
0.71%
Current Stock Chart for FRESENIUS SE & CO KGAA (FRE)

Related News

No related news articles were found.

fresenius se & co kgaa (FRE) Related Businessweek News

No Related Businessweek News Found

fresenius se & co kgaa (FRE) Details

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment provides products for hemodialysis and peritoneal dialysis. This segment offers dialyzers, dialysis machines, and renal pharmaceuticals, as well as dialysis- related services. As of December 31, 2014, it treated approximately 285,312 patients at 3,361 dialysis clinics. The Fresenius Kabi segment provides therapy and care for chronically and critically ill patients. This segment offers intravenously administered generic drugs, such as anesthetics, anti-infectives, and analgesics, as well as drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps; products used in the collection and processing whole blood and blood components, as well as in transfusion medicine. The Fresenius Helios segment operated approximately 110 hospitals, including 86 acute care hospitals and 24 post acute care clinics; 47 outpatient clinics; and 15 nursing homes. The Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as provides maintenance, technical, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg, Germany.

220,339 Employees
Last Reported Date: 08/4/15
Founded in 1912

fresenius se & co kgaa (FRE) Top Compensated Officers

Chairman of the Management Board - Fresenius ...
Total Annual Compensation: €2.4M
Chief Financial Officer of Fresenius Manageme...
Total Annual Compensation: €1.5M
Chief Legal & Compliance Officer of Fresenius...
Total Annual Compensation: €1.1M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €2.9M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €1.6M
Compensation as of Fiscal Year 2014.

fresenius se & co kgaa (FRE) Key Developments

Fresenius Reports Earnings Results for the Second Quarter of 2015; Revises Earnings Guidance for 2015

Fresenius reported earnings results for the second quarter of 2015. Net profit in the second quarter alone surged 35% to EUR 350 million (USD 384.2 million), due to the strong performance of all units. Earnings before interest and tax (EBIT) jumped 28% to EUR 971 million on sales increase of 26% to EUR 9.6 billion. The company raised its full-year guidance prompted by its strong performance in the first half of 2015. The company now expects net profit in the full 2015 to grow in the range of 18% to 21% at constant exchange rates, compared with the previous guidance for growth of between 13% and 16%. Sales are expected to advance in the range of 8% to 10%, compared with the previous expectations of growth in the range of 7% to 10%.

Fresenius SE & Co Mulls Acquisitions

Fresenius SE & Co KGaA (DB:FRE) is seeking acquisitions. Mark Schneider, Chairman of the Management Board of Fresenius SE & Co, said, “And we continue to look at small to medium-sized acquisitions, as you know, and I think there's always an opportunity across some of our four businesses.”

Fresenius SE & Co KGaA Presents at Deutsche Bank dbAccess German, Swiss & Austrian Conference 2015, Jun-18-2015

Fresenius SE & Co KGaA Presents at Deutsche Bank dbAccess German, Swiss & Austrian Conference 2015, Jun-18-2015 . Venue: Berlin, Germany.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRE:GR €61.95 EUR +0.442

FRE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Danone SA €54.13 EUR -0.23
DaVita HealthCare Partners Inc $74.05 USD -1.59
Fresenius Medical Care AG & Co KGaA €66.95 EUR +0.462
Mead Johnson Nutrition Co $76.04 USD -2.30
Yakult Honsha Co Ltd ¥6,210 JPY -200.00
View Industry Companies
 

Industry Analysis

FRE

Industry Average

Valuation FRE Industry Range
Price/Earnings 29.2x
Price/Sales 1.3x
Price/Book 3.4x
Price/Cash Flow 29.1x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS SE & CO KGAA, please visit www.fresenius.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.